Humira treatment for psoriasis
Humira (adalimumab) first won FDA approval in 2002 and is currently used to treat psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), ankylosing spondylitis and Crohn’s disease. Humira is very effective, with more than two-thirds of patients in clinical trials experiencing a 75% reduction in psoriasis severity (PASI 75) after 16 weeks of treatment, including about 40% of patients who achieved a 90% reduction in psoriasis severity.
How is it administered? Humira is administered by self-injection under the skin, typically once every two weeks.
Advantages Humira is highly effective, with self-dosing every other week. In addition, it is a fully human protein, which may make it less allergenic than biologics that are partially derived from animals. While not used as long or as often as Enbrel or Remicade, its use in more than 200,000 patients worldwide for a variety of diseases is a significant figure that helps the medical community’s ability to assess Humira’s risks.
Drawbacks Like all of the TNF-inhibitors, Humira has the potential to cause the rare but serious side effects described here.
How does it work? Humira is a human antibody that binds to and inactivates TNF-alpha. This reduces TNF-alpha levels in the body, which leads to improvement in psoriasis symptoms.
The company that markets this treatment is among those that have programs to help people afford their treatments. Learn more here: Psoriasis Prescription Payment Assistance Programs.
[More info: Humira website.]
[More info: Biologics for psoriasis.]
[More info: Psoriasis Treatments.]